SBRA 30011
Latest Information Update: 13 Jun 2001
Price :
$50 *
At a glance
- Originator Nonindustrial source
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 13 Jun 2001 No-Development-Reported for Cancer in USA (Unknown route)
- 16 May 1997 Preclinical development for Cancer in USA (Unknown route)